ArticleNeuro-oncology2023
Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: A longitudinal study spanning two decades.
Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07628647 (Pilot Study of the Living Well With Brain Cancer Intervention), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study of the Living Well With Brain Cancer Intervention
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Contribution of cognitive function and fatigue to health-related quality of life in patients withNeuro-oncology practice · 2026Article
- Symptom burden in young adult brain tumor survivors: Key intervention targets based on patient-reported outcome network analyses.Neuro-oncology practice · 2026Article
- Multiscale network perspectives on glioma: from tumour biology to symptoms, survival and treatment.Nature reviews. Neurology · 2026Review
- Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.Neuro-oncology · 2025Observational
- The deleterious effect of WHO grade II diffuse glioma on socioeconomic status as evaluated through occupation.Scientific reports · 2025Article
- Use of psychotropic medications among glioma patients in Denmark, Norway, Sweden, and Wales.Journal of neuro-oncology · 2025Article
- Neurocognitive function in lower grade glioma patients selected for proton radiotherapy: real-world data from a prospective cohort study.Journal of neuro-oncology · 2025Article
- Factors contributing to variability in neurocognitive performance before glioma neurosurgery.Neuro-oncology practice · 2025Article
- Health-related quality of life in 62 patients with diffuse low-grade glioma during a non-therapeutic and progression-free phase: a cross-sectional study.Journal of neuro-oncology · 2025Article
- Symptom management in isocitrate dehydrogenase mutant glioma.Neuro-oncology practice · 2025Review
- Efficacy of hybrid remote neuropsychological rehabilitation on cognitive complaints in post-therapeutic lower-grade glioma: the FREEDOME randomized study protocol.Frontiers in psychology · 2025Article
- Identifying and understanding how people living with a lower-grade glioma engage in self-management.Journal of cancer survivorship : research and practice · 2024Article
- Long-term autonomy, professional activities, cognition, and overall survival after awake functional-based surgery in patients with IDH-mutant grade 2 gliomas: a retrospective cohort study.The Lancet regional health. Europe · 2024Article
- Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- "It changes everything": Understanding how people experience the impact of living with a lower-grade glioma.Neuro-oncology practice · 2024Article
- Understanding supported self-management for people living with a lower-grade glioma: Implementation considerations through the lens of normalisation process theory.Health expectations : an international journal of public participation in health care and health policy · 2024Article
- Extracellular vesicles from GABAergic but not glutamatergic neurons protect against neurological dysfunction following cranial irradiation.Scientific reports · 2024Article
- 'A Constant Black Cloud': The Emotional Impact of Informal Caregiving for Someone With a Lower-Grade Glioma.Qualitative health research · 2024Article
- High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.Frontiers in oncology · 2024Review
- Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up.Journal of neuro-oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile patients with diffuse low-grade glioma (LGG) often survive for years, there is a risk of tumor progression which may impact patients' long-term health-related quality of life (HRQOL) and neurocognitive functioning (NCF). We present a follow-up of LGG patients and their informal caregivers (T3) who took part in our previous HRQOL investigations (T1, M = 7 and T2 M = 13 years after diagnosis).
methodsParticipants completed HRQOL (short form-36 health survey [SF-36]; EORTC-BN20), fatigue (Checklist Individual Strength [CIS]), and depression (Center for Epidemiological Studies-Depression [CES-D]) questionnaires and underwent NCF assessments. T3 scores were compared with matched controls. Changes over time (T1-T2-T3) on group and participant level were assessed. Where available, histology of the initial tumor was revised and immunohistochemical staining for IDH1 R132H mutant protein was performed.
resultsThirty patients and nineteen caregivers participated. Of N = 11 with tissue available, 3 patients had confirmed diffuse LGG. At T3, patients (M = 26 years after diagnosis) had HRQOL and NCF similar to, or better than controls, yet 23.3% and 53.3% scored above the cut-off for depression (≥16 CES-D) and fatigue (≥35 CIS), respectively. Caregivers' HRQOL was similar to controls but reported high rates of fatigue (63.2%). Over time, patients' mental health improved (P < .05). Minimal detectable change in HRQOL over time was observed in individual patients (30% improvement; 23.3% decline; 20% both improvement and decline) with 23.3% remaining stable. NCF remained stable or improved in 82.8% of patients.
conclusionsWhile HRQOL and NCF do not appear greatly impacted during long-term survivorship in LGG, depressive symptoms and fatigue are persistent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.